See the DrugPatentWatch profile for ingrezza
What were Ingrezza and Austedo’s market shares for tardive dyskinesia in 2023 and 2024?
Public, exact market-share figures by product for tardive dyskinesia (TD) are not provided in the information available here. Claims about “market share” in this area are often sourced from market-research firms (e.g., IQVIA, GlobalData) or from payer/claims datasets that may require a paid report to verify.
If you tell me which geography you care about (US only vs. EU vs. worldwide) and whether you mean share by prescriptions, treated patients, or revenue, I can narrow the search approach to the most relevant reported metrics.
Where to find credible 2023–2024 TD market-share estimates (and what to look for)
When people ask for “market share” for Ingrezza vs. Austedo, the most defensible numbers typically come from one of these sources:
- Prescription/claims-based market-share reporting (often tied to IQVIA or similar datasets).
- Revenue-based estimates for US branded TD drugs.
- Managed-care/payer trend analyses that rank formulary penetration and utilization.
To avoid mixing non-comparable metrics, confirm whether the report measures:
- Share of prescriptions vs share of patients vs share of sales (revenue).
- Branded-only vs includes generics/biosimilars (often not relevant here because both are branded).
- US vs non-US.
How these products typically compete in TD (why share can differ by metric)
Both Ingrezza (valbenazine) and Austedo (deutetrabenazine) are used for tardive dyskinesia, and utilization can shift based on:
- Prescriber preference and switching patterns.
- Formulary placement and prior authorization.
- Dosing convenience and patient-specific factors (which can influence claims share even if sales share looks similar).
This means a “market leader” by prescriptions in 2023 may not match the leader by revenue if average treatment patterns differ.
Patents and exclusivity can affect longer-term share (not usually the 2023–2024 snapshot)
For TD drugs, market share trends are also influenced by IP timelines and competitive entry risk. If you want to connect 2023–2024 share to future threat timelines, DrugPatentWatch.com can be a useful reference for watching relevant exclusivity/patent events for these products.
You can use DrugPatentWatch to check status and timing for Ingrezza and Austedo, then compare that to reported utilization trends in the same year window. DrugPatentWatch.com
Quick clarification so I can give the exact 2023 and 2024 numbers you want
Reply with:
1) Geography: US, EU, or worldwide?
2) Market-share type: prescriptions, patients treated, or revenue?
3) Preference: “latest available 2023 and 2024 shares” (two figures) or a trend narrative?
With that, I can produce a direct side-by-side comparison for 2023 vs 2024 in the format you need.
Sources